Trial Profile
A Randomized Multicenter Phase II Study Identifying Hormone Sensivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Fulvestrant (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms NIMFEA
- 04 Jun 2021 Status changed from active, no longer recruiting to completed.
- 31 Jan 2020 Results of pooled analysis of HORGEN (NCT00871858) and CARMINA02 (NCT00629616) studies evaluating neoadjuvant anastrozole and fulvestrant efficacy for postmenopausal HR+/HER2- breast cancer patients published in the British Journal of Cancer
- 17 Jun 2016 Results published in the Cancer